| 2025 MOQC MEASURES | ||||
|---|---|---|---|---|
| Measure Number | Measure Description | Target | MEQC | VBR |
| 101b | Tobacco cessation counseling or referral for tobacco users once a year | 70 | X | X |
| 103 | Designated advocate documented on a legally recognized document in the inpatient or outpatient medical record | 20 | X | |
| 108a | Complete family history documented for patients with invasive cancer | 35 | X | |
| 114 | NK1RA administered for low or moderate emetic risk cycle 1 chemotherapy (lower score = better) | 10 | X | X |
| 115 | NK1RA and olanzapine prescribed or administered with high emetic risk chemotherapy | 60 | X | X |
| 126a | Hospice enrollment | 65 | X | |
| 126b | Hospice enrollment more than 7 days before death | 60 | X | |
| 126c | Hospice enrollment more than 30 days before death | 30 | X | |
| 127a | Any anticancer therapy, including chemotherapy, administered within the last 14 days of life (lower score = better) | |||
| 128 | Non-chemotherapy anticancer agent administered within the last 14 days of life (lower score = better) | |||
| 129 | Palliative care consultation more than 90 days before death | 20 | X | |
| 130 | Beginning a new anticancer regimen within the last 14 days of life (lower score = better) | 10 | X | |
| GYNECOLOGIC ONCOLOGY ONLY MEASURES | ||||
| Measure Number | Measure Description | Target | MEQC | VBR |
| 116 | Prescribing of opioids for patients after laparoscopic or open hysterectomy | 9 pills or fewer | X | X |
| 123 | Days from surgery to chemotherapy start | 28 days or less | X | X |